Xencor (NASDAQ:XNCR) Shares Cross Above Fifty Day Moving Average – Here’s What Happened

Xencor, Inc. (NASDAQ:XNCR) passed above its 50 day moving average during trading on Monday . The stock has a 50 day moving average of $12.19 and traded as high as $12.50. Xencor shares last traded at $12.05, with a volume of 1,516,697 shares traded.

Analyst Ratings Changes

Several brokerages recently issued reports on XNCR. Weiss Ratings reiterated a “sell (d-)” rating on shares of Xencor in a research report on Monday, December 29th. Barclays lifted their price target on Xencor from $26.00 to $27.00 and gave the company an “overweight” rating in a research report on Thursday, February 26th. Wall Street Zen cut Xencor from a “hold” rating to a “sell” rating in a research note on Saturday, February 28th. Finally, Truist Financial began coverage on Xencor in a research report on Monday, November 24th. They set a “buy” rating and a $29.00 price objective for the company. Eight equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Xencor has an average rating of “Moderate Buy” and an average target price of $25.00.

Xencor Price Performance

The company has a current ratio of 6.25, a quick ratio of 6.25 and a debt-to-equity ratio of 0.12. The company has a market cap of $883.73 million, a PE ratio of -9.72 and a beta of 0.95. The firm has a 50 day moving average of $12.19 and a two-hundred day moving average of $13.30.

Xencor (NASDAQ:XNCR) last released its earnings results on Wednesday, February 25th. The biopharmaceutical company reported ($0.09) EPS for the quarter, topping the consensus estimate of ($0.64) by $0.55. Xencor had a negative return on equity of 14.58% and a negative net margin of 73.20%.The business had revenue of $28.24 million for the quarter, compared to the consensus estimate of $29.97 million. During the same period in the previous year, the company posted ($0.62) earnings per share. The company’s revenue for the quarter was down 46.6% compared to the same quarter last year. Research analysts predict that Xencor, Inc. will post -3.68 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, SVP Celia Eckert sold 3,244 shares of the stock in a transaction dated Thursday, March 5th. The shares were sold at an average price of $11.25, for a total transaction of $36,495.00. Following the sale, the senior vice president directly owned 78,685 shares of the company’s stock, valued at approximately $885,206.25. This represents a 3.96% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Bassil I. Dahiyat sold 14,870 shares of Xencor stock in a transaction dated Thursday, March 5th. The stock was sold at an average price of $11.25, for a total transaction of $167,287.50. Following the completion of the transaction, the chief executive officer directly owned 552,922 shares of the company’s stock, valued at $6,220,372.50. This trade represents a 2.62% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 44,020 shares of company stock worth $499,817 in the last quarter. Corporate insiders own 4.76% of the company’s stock.

Institutional Trading of Xencor

Institutional investors have recently added to or reduced their stakes in the business. AQR Capital Management LLC purchased a new position in shares of Xencor in the first quarter worth $438,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in Xencor by 9.1% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 44,047 shares of the biopharmaceutical company’s stock worth $471,000 after buying an additional 3,692 shares in the last quarter. Goldman Sachs Group Inc. raised its position in Xencor by 89.9% in the 1st quarter. Goldman Sachs Group Inc. now owns 726,734 shares of the biopharmaceutical company’s stock worth $7,732,000 after buying an additional 344,088 shares during the last quarter. PNC Financial Services Group Inc. lifted its stake in Xencor by 82.8% during the 2nd quarter. PNC Financial Services Group Inc. now owns 5,982 shares of the biopharmaceutical company’s stock valued at $47,000 after acquiring an additional 2,709 shares during the period. Finally, Geode Capital Management LLC lifted its stake in Xencor by 1.8% during the 2nd quarter. Geode Capital Management LLC now owns 1,703,664 shares of the biopharmaceutical company’s stock valued at $13,393,000 after acquiring an additional 29,316 shares during the period.

About Xencor

Xencor, Inc is a clinical-stage biopharmaceutical company focused on the design and development of engineered protein therapeutics for the treatment of autoimmune diseases, cancer and neurological disorders. The company applies its proprietary XmAb® platform to manipulate antibody structure and function, creating molecules with enhanced immune engagement and extended half-life. Xencor’s research programs span a range of therapeutic modalities, including monoclonal antibodies, bispecific antibodies and cytokine-based fusion proteins.

The XmAb® platform enables precise modification of the Fc region to augment key properties such as receptor binding, effector function and pharmacokinetics.